Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder without a cure or prevention to date. Hyperphosphorylated tau forms the neurofibrillary tangles (NFTs) that correlate well with the progression of cognitive impairments. Animal studies demonstrated the pathogenic role of hyperphosphorylated tau. Understanding how abnormal phosphorylation renders a normal tau prone to form toxic fibrils is key to delineating molecular pathology and to developing efficacious drugs for AD. Production of a tau bearing the disease-relevant hyperphosphorylation and molecular characters is a pivotal step. Here, we report the preparation and characterization of a recombinant hyperphosphorylated tau (p-tau) with strong relevance to disease. P-tau generated by the PIMAX approach resulted in phosphorylation at multiple epitopes linked to the progression of AD neuropathology. In stark contrast to unmodified tau that required an aggregation inducer, and which had minimal effects on cell functions, p-tau formed inducer-free fibrils that triggered a spike of mitochondrial superoxide, induced apoptosis, and caused cell death at sub-micromolar concentrations. P-tau-induced apoptosis was suppressed by inhibitors for reactive oxygen species. Hyperphosphorylation apparently caused rapid formation of a disease-related conformation. In both aggregation and cytotoxicity, p-tau exhibited seeding activities that converted the unmodified tau into a cytotoxic species with an increased propensity for fibrillization. These characters of p-tau are consistent with the emerging view that hyperphosphorylation causes tau to become an aggregation-prone and cytotoxic species that underlies diffusible pathology in AD and other tauopathies. Our results further suggest that p-tau affords a feasible tool for Alzheimer's disease mechanistic and drug discovery studies.

Highlights

  • Thirty million people in the world suffer from Alzheimer’s disease (AD)

  • Recombinant hyperphosphorylated tau isoforms produced by PIMAX

  • Recombinant tau allows for easy access, but lacks the disease-associated hyperphosphorylation, whereas tau extracted from patients or transgenic animals likely contained interfering post-translational modifications and other biomolecules

Read more

Summary

Introduction

Thirty million people in the world suffer from Alzheimer’s disease (AD). This number is expected to triple by 2050, according to the World Health Organization. Major biomarkers for AD include the senile plaques of Aβ peptide precipitates [1], and the neurofibrillary tangles (NFTs) of fibrillar hyperphosphorylated tau protein [2]. Recurring failures of anti-Aβ drug trials to improve cognition argue strongly against the notion that dementia involves solely Aβ[4]. The spatiotemporal distribution of NFTs correlates with the advancement of cognitive impairments [5,6,7,8]. NFTs consist of fibrils of abnormally phosphorylated tau protein. GSK-3β (glycogen synthase kinase 3β) and CDK5 (cyclindependent kinase 5) are among the prime suspects for tau hyperphosphorylation [13]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call